Abstract: Non-enzymatic modification of proteins in hyperglycemia is a major proposed mechanism of diabetic complications. Specifically, advanced glycation end products (AGEs) derived from hyperglycemia-induced reactive carbonyl species (RCS) can have pathogenic consequences when they target functionally critical protein residues. Modification of a small number of these critical residues, often undetectable by the methodologies relying on measurements of total AGE levels, can cause significant functional damage. Therefore, detection of specific sites of protein damage in diabetes is central to understanding the molecular basis of diabetic complications and for identification of biomarkers which are mechanistically linked to the disease. The current paradigm of RCS-derived protein damage places a major focus on methylglyoxal (MGO), an intermediate of cellular glycolysis. We propose that glyoxal (GO) is a major contributor to extracellular matrix (ECM) damage in diabetes. Here, we review the current knowledge and provide new data about GO-derived sitespecific ECM modification in experimental diabetes.
Introduction
Diabetes is one of the major human diseases, which leads to serious complications such as neuropathy, retinopathy, microvascular disease, atherosclerosis, and nephropathy. A proposed unifying mechanism of the pathobiology of diabetic complications considers several pathogenic pathways including a rise in the levels of intracellular methylglyoxal (MGO) due to inhibition of glycolysis, and the resulting increase in MGO-derived protein modifications ( [1] and Figure 1 ). Unlike glucose which modifies primarily lysine residues, MGO and other reactive carbonyl species (RCS) react preferentially with arginine residues with high reaction rates [2] , and may play an important role in pathogenesis because of high abundance of arginine residues within protein active sites [3] . Indeed, in hyperglycemia, metabolically derived MGO has been implicated in modification and functional impairment of a number of proteins [1, [4] [5] [6] . However, in the extracellular diabetic milieu other mechanisms including autoxidation of glucose and peroxidation of lipids may also contribute to specific RCSderived protein damage ( Figure 1 ). In this case, glyoxal (GO) may play a key role in protein damage because it is a major product of glucose and lipid oxidation [7] [8] [9] [10] .
GO-derived advanced glycation end products (AGEs) and their impact on protein structure and function
GO in tissues can originate from both exogenous and endogenous sources. The role of the exogenous sources, which include GO-rich foods and environmental pollutants, in modulation of GO tissue levels and GO-derived tissue damage is unknown [11] . Endogenous GO can derive from such diverse pathways as peroxidation of lipids [10] , oxidation of α-amino acids by myeloperoxidase system [12] , and photodegradation of retinoid compounds [13] . In diabetes, autoxidation of glucose and oxidation of glucose-protein adducts are important sources of endogenous GO production with glucose autoxidation being the major pathway [7, 14, 15] .
GO can modify proteins via adduction of lysine, arginine and cysteine residues as well as formation of lysinelysine and lysine-arginine crosslinks [14, [16] [17] [18] . The levels of GO-derived modifications such as N ε -(carboxymethyl)-lysine (CML) and N δ -(5-hydro-4-imidazolon-2-yl) (G-H1) have been shown to correlate with diabetic complications, suggesting their potential contribution to pathogenesis [19] . The mechanisms of such contribution are still unknown but several studies demonstrated the detrimental impact of GO-derived modifications on function of proteins involved in antioxidant defenses, neurodegenerative disorders, and cell-matrix interactions [20] [21] [22] .
Site-specific protein modification by GO: difference between modification and functional damage
It is yet unclear whether GO-derived protein modifications that accumulate in diabetes have mechanistic In the cell (left), inhibition of glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in hyperglycemia via overproduction of mitochondrial superoxide causes accumulation of GAP and excessive intracellular formation of methylglyoxal (MGO); this MGO modifies cellular and extracellular proteins [1] . Outside the cell (right), glucose, lipids, and glycated proteins are oxidized to form a major product glyoxal (GO) [7] [8] [9] [10] ; this GO preferentially modifies extracellular proteins. significance in pathogenesis or simply indicate secondary glycoxidative damage. The measurements of total levels of protein-GO adducts cannot provide significant insights into the pathogenic mechanisms because only a small fraction of amino acids susceptible to these modifications is located within functionally important protein sites. Therefore, depending on the microenvironment and reactivity of specific amino acid side chains, levels of GO adducts may not always reflect functional protein damage as schematically illustrated in Figure 2 . Indeed, the total levels of specific protein adducts such as CML are often not reliable as disease biomarkers [23, 24] . By contrast, determination of site-specific modifications within functionally important protein sites may offer direct insight into early pathogenic events. These sitespecific AGE modifications could also be utilized as more reliable disease biomarkers which are directly linked to pathogenic mechanisms.
In in vitro model systems, analysis of GO adducts at specific protein sites allows for a more precise understanding of the impact of these modifications on protein structure and function. In RNase treated with purified GO, formation of GO-arginine adducts was shown to be a highly site-specific process [25] . Primary sites of the adduct formation were Arg 39 and Arg
85
, the arginine residues closest to the active site of the RNase [25] . When lysozyme was incubated with glucose under oxidative conditions, there was a significant increase in the levels of arginine G-H1 adducts [9] . One of the primary modification sites was located at Arg 114 , a residue critical for lysozyme activity [26] . This residue was effectively protected from GO modification when glucose autoxidation was inhibited under non-oxidative solution conditions [9] . These results demonstrated that GO produced during autoxidation of glucose can modify critical arginine residues, thus causing functional damage to proteins.
Modification of extracellular matrix (ECM) proteins by GO
ECM proteins are significantly more susceptible to glycoxidative damage compared with both circulating and intracellular proteins because they have relatively long life times. For example, human skin and cartilage collagens have half-lives of approximately 15 and approximately 117 years, respectively [27] . ECM proteins of renal glomerular basement membrane are also relatively long-lived with an average half-life of more than 100 days [28] . Slow ECM turnover rates allow modifications to accumulate to higher levels so they are more likely to interfere with protein function [27] . In addition, ECM proteins are much more susceptible to glycoxidative damage compared with intracellular proteins because they lack protection afforded by generally reducing cellular environment and robust cellular enzymatic defenses including carbonyl detoxification and deglycation [29, 30] .
Consequently, GO-derived modifications are significantly increased in ECM subjected to chronic hyperglycemia and carbonyl stress of diabetes. CML adducts were detected in diabetic experimental models and clinical renal specimens taken from diabetic patients [31] [32] [33] . High level of CML was found in diabetic renal glomerular basement membrane and in ECM of human retina [34, 35] . Similarly, elevated GO-derived arginine adducts were found in ECM proteins isolated from a diabetic animal model and from diabetic patients [36, 37] .
In the ECM, there are potentially three types of functionally critical sites that could be damaged upon modification by GO: (i) the cellular receptor binding sites conferring cell-ECM interactions; (ii) the proteolytic cleavage sites important in ECM turnover; and (iii) the subunit interface sites critical for ECM assembly.
Cell-ECM interactions
Mechanistic in vitro studies have suggested that modification of arginine residues within integrin-binding motifs using GO can perturb integrin-dependent cell-ECM adhesion [9, 22] . The disruption of these integrin-ECM interactions may be important in pathogenesis as mice lacking integrin α 1 β 1 , a principal collagen IV receptor, developed more severe expansion of mesangial ECM than their wild type counterparts [33] . By contrast, modification of lysine residues in collagen IV to CML had no effect on cell adhesion to this ECM protein, but specifically inhibited cell proliferation [38] . This observation suggests that specific modifications of ECM by GO derived from glucose autoxidation may affect distinct cell functions by interfering with binding of different cellular receptors.
Functioning of one such receptors, receptor for advanced glycation end products (RAGE), may also be affected by GO because modification of lysine residues to CML is required for RAGE binding [39] . However, the importance of circulating CML-modified proteins as RAGE ligands has been questioned based on a relatively low degree of modification of circulating proteins under physiological conditions [40] . Compared with circulating proteins, long-lived ECM proteins can accumulate much higher levels of CML under pathophysiological conditions in vivo [36] . This could make glycoxidized ECM a better RAGE ligand capable of providing multiple binding sites necessary for RAGE dimerization and activation [41] . Modification of collagen in the presence of glucose has been shown to modulate neutrophil adhesion and migration via the RAGE-dependent PI3K signaling pathway [42] . Because CML can derive from glucose and lipids via the GO route [10, 14, 15] , GO is likely to play a role in this RAGEdependent modulation. Identification of CML clusters with potential of binding RAGE in diabetic ECM will help to determine the mechanism of RAGE-ECM interactions.
ECM turnover
Excessive accumulation of the ECM is a well-known lesion in diabetic complications [43] . The role of matrix glycation in this phenomenon is supported by detection of AGE crosslinks in tissues and by decreased activity of specific matrix metalloproteases (MMPs) towards glycated ECM proteins [44, 45] . The effect of GO-derived crosslinks on ECM turnover is probably minimal because major physiological crosslinks derive via non-oxidative pathways [45] . However, there may be other mechanisms besides glucose-induced crosslinking that modulate ECM turnover. One example is engagement of cellular receptors by glycoxidized ECM. Cells grown on glucose-modified collagen expressed less of MMP-2 and more of endogenous collagen IV and MMP inhibitor TIMP-1 compared with cells grown on unmodified collagen [38, 46] . Exposure of tenocytes to CML-collagen I increased intracellular activity of transglutaminase, an enzyme that catalyzes formation of non-AGE crosslinks in ECM [47] . In addition, non-crosslink GO-derived modifications such as CML, G-H1, and carboxymethyl arginine may contribute to the lower digestibility of diabetic ECM because the consensus cleavage sites of many MMPs contain lysine and arginine residues [48] . Identification of GO-derived non-crosslink modifications within ECM receptor binding and protease cleavage sites may provide important clues about the role of GO in matrix turnover.
ECM assembly and stability
There are some indications that glycoxidation of ECM proteins may affect their conformation and assembly. For example, the conserved regions of NC1 domains of collagen IV critical in chain recognition during protomer assembly are enriched in arginine and lysine residues [49] . It has been reported that collagen modified in vitro with either GO or glucose had greater thermal stability, mean fiber radius, and pore size compared with unmodified collagen [50] [51] [52] . However, these studies were performed at supraphysiological concentrations of either glucose or GO, a condition which favors crosslink formation. Determination of GO-derived modifications within specific sites at different ECM assembly interfaces in vivo may prove critical for understanding how GO affects ECM network stability.
To provide initial insights into this question, we isolated collagen IV NC1 domains, which play a key role in the collagen IV network assembly, from renal ECM of control and streptozotocin-diabetic rats. Pooled samples from three animals per treatment group were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) following proteolytic digestion at sequence coverage of > 97% as previously described [9] . We found that GO-derived G-H1 modification of Arg 169 (R 169 ) in the α1NC1 domain was increased from approximately 7% in control animals to over 21% in diabetic animals ( Table 1) . In diabetic animals treated with pyridoxamine (PM), a compound which can inhibit glucose autoxidation and lipoxidation [9, 53, 54] , the degree of modification was attenuated to approximately 14% ( Table 1) .
The effect of this modification on NC1 domain structure was investigated using molecular dynamics (MD) simulations. Analyses of MD simulations show that the side chain of unmodified R 169 residue is bridging the interface between A and B subdomains of the α1NC1 monomer (Figure 3 that G-H1 169 is unable to form comparable hydrogen bonds (Figure 3, insets) . Therefore, our MD results predict that G-H1 169 reduces enthalpic stabilization and is thus consistent with the negative impact of G-H1 169 on conformational stability of the NC1 domain. The finding that PM, a prospective drug in treatment of diabetic nephropathy [55] , inhibited G-H1 169 formation suggests a role for stability of NC1 domains in diabetic renal pathology.
Conclusions
Reactive carbonyl species are key agents in propagation of diabetic protein damage to arginine residues within the sites critical to protein function. Although the primary focus so far has been on glycolysis byproduct MGO, GO may be equally important in protein damage, especially in the ECM. In particular, stability of collagen IV networks may be compromised in diabetes due to GO-modified arginine residues within assembly interface of collagen IV NC1 domains. Because GO can potentially modify a variety of different ECM functional sites, it may be an important pathogenic intermediate whereby glucose and lipid oxidation causes damage to ECM proteins, thus contributing to complications of diabetes.
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